Noble Financial Keeps Galena (GALE) at 'Buy'; Interim NeuVax Phase 3 Data Now in Focus
Tweet Send to a Friend
Noble Financial maintains its Buy rating and $3.50 price target on Galena Biopharma, Inc. (Nasdaq: GALE) following Q1 results and ...
This is a premium only article. To continue reading this and other premium stock market news articles please sign-in or upgrade to StreetInsider.com Premium below (Free Trial) LEARN MORE
This is a premium only article. To continue reading this and other premium stock market news articles please sign-in or upgrade to StreetInsider.com Premium below (Free Trial) LEARN MORE
